Literature DB >> 16204971

Improved quantitative determination of total and unbound concentrations of six teicoplanin components in human plasma by high performance liquid chromatography.

Kazuhiko Hanada1, Akiko Kobayashi, Yumi Okamori, Toshimi Kimura, Hiroyasu Ogata.   

Abstract

Total and unbound concentrations of six teicoplanin components in human plasma were determined by high-performance liquid chromatography with a coextractive cleanup technique. Unbound concentrations of teicoplanin components were estimated after ultrafiltration of plasma. For determination of each component in plasma, plasma was deproteinized with acetonitrile and the supernatant was shaken for 60 s with chloroform under acidic conditions. The recoveries of A3-1, A2-1, A2-2, A2-3, A2-4 and A2-5 were greater than 88%. The within-day and between-day coefficients of variation were 1.3-8.8% and 2.8-11.9%, respectively. The limits of detection in ultrafiltered plasma for each component were 0.82, 2.87, 4.23, 3.36, 7.33 and 4.93 nM, respectively. A good correlation was observed between the FPIA and HPLC methods when total concentrations of each teicoplanin component in patient plasma were determined. The analytical methods established in this study are suitable for determining the total and unbound concentrations of six components of teicoplanin in human plasma and for studying the pharmacokinetics of teicoplanin components in patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204971     DOI: 10.1248/bpb.28.2023

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  1 in total

1.  Evaluation of the QMS® Teicoplanin Immunoassay (ThermoFisher Scientific) on Cobas® 8000 System (Roche Diagnostics) and comparison to fluorescence polarization immunoassay for the determination of teicoplanin concentrations in human plasma.

Authors:  Eric Dailly; François Fraissinet; Guillaume Deslandes; Régis Bouquié; Pascale Jolliet
Journal:  J Clin Lab Anal       Date:  2013-02-01       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.